If you are not happy with the results below please do another search
Recently published research [1] provides new hope for a potential cure for the devastating cystic fibrosis disease. In the study, a research collaboration demonstrated how they corrected mutations that cause cystic fibrosis in cultured human stem cells using a CRISPR/Cas9 variant technique called prime editing to replace the ‘faulty’ piece of DNA with a healthy […]
As a partner of the Fraunhofer Competence Network Quantum Computing, the German Cancer Research Center is planning to use the quantu m computer in Ehningen, Baden-Württemberg, to develop individually effective cancer treatment methods.
DeepMind has partnered with the European Molecular Biology Laboratory (EMBL), Europe’s flagship laboratory for the life sciences, to make the most complete and accurate database yet of predicted protein structure models for the human proteome.
Personalized tumour treatments are expensive. This particularly applies to individual cancer therapies based on gene-modified T cells. Currently, they are produced manually or, at best, in a partially automated process. In a collaboration project “ProCell for Patient” two hospitals are currently working with Optima Pharma to develop an automated unit for the decentralized production of […]
The pace of acute therapy and vaccine development for COVID have been dizzying. But even as we hope a route to bringing the pandemic under control is within sight, we’re now facing the possibility of another urgent public health emergency thanks to what’s known as long COVID, a group of symptoms that last long after […]
International Hospital speaks to Masaharu Fukumoto, Senior Vice President Fujifilm Medical Systems Europe about the company’s recent acquisition of Hitachi Healthcare’s diagnostic imaging business, the restructuring of the company and the way forward.
By Lara Marks – Visiting Research Fellow, History of Biomedical Sciences, University of Cambridge and Ankur Mutreja – Group Leader, Global Health (Infectious Diseases), University of Cambridge ————————————– SARS-CoV-2, the virus responsible for COVID-19, has turned the world upside down. Experts have predicted that it will claim the lives of between […]
By Hamish McCallum Director, Centre for Planetary Health and Food Security, Griffith University The COVID-19 pandemic is a dramatic demonstration of evolution in action. Evolutionary theory explains much of what has already happened, predicts what will happen in the future and suggests which management strategies are likely to be the most effective. For […]
Intellia Therapeutics and Regeneron Pharmaceuticals have presented positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
COVID-19 has caused a crisis for building owners and landlords – both in the public and private sectors. Patterns of work and public service are clearly changing as a result of the crisis and its aftermath.
Parklaan 54a
5613 BH
Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
